Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen + dexamethasone with bortezomib or daratumumab in relapsed or relapsed‑refractory multiple myeloma
2017-002120-24Phase 2Completed
- Sponsor
- Oncopeptides AB
- Start
- Aug 2017
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan flufenamide in multiple myeloma (MM) (2 arms), sponsored by Oncopeptides AB. Started Aug 2017; status: completed.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-002120-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002120-24.